From FDA labels and ClinicalTrials.gov

Do GLP-1s help kidney disease?

Last updated

If your prescriber prescribes one: the lowest self-pay GLP-1 prices now

  • Lowest compounded tirzepatide on a monthly plan, not FDA-approved

    Collective

    $69/mo + $199/yr membership · about $86 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest compounded semaglutide on a monthly plan, not FDA-approved

    Collective

    $59/mo + $199/yr membership · about $76 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest FDA-approved, starting dose

    LillyDirect (Eli Lilly)

    from $149/mo

  • Lowest FDA-approved injection, starting dose

    NovoCare (Novo Nordisk)

    $199/fill initially

FDA has approved Ozempic for this, in the words of each label below. FLOW (Semaglutide): In people with type 2 diabetes and chronic kidney disease, major kidney events or death from kidney or heart causes were 24% less likely on semaglutide (331 against 410 first events; hazard ratio 0.76). N Engl J Med, 2024 (pubmed.ncbi.nlm.nih.gov/38785209). ClinicalTrials.gov lists 69 trials of these medicines on it: 15 with posted results and 18 recruiting now.

Read from the registry and PubMed every day. The newest update here is Nov 18, 2026.

FDA approved

What each label says on kidney disease

The approved use, word for word from each current label.

  • Ozempic: to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease.
Published results

What the largest trials on kidney disease found

Each read in the paper's abstract on Nov 6, 2026. Trials differ in who took part and how long they ran.

FLOW

Semaglutide · 3,533 people · Better than the comparison · Placebo-controlled randomized trial

In people with type 2 diabetes and chronic kidney disease, major kidney events or death from kidney or heart causes were 24% less likely on semaglutide (331 against 410 first events; hazard ratio 0.76).

N Engl J Med, 2024 (pubmed.ncbi.nlm.nih.gov/38785209)

The registry

Trials on kidney disease, by medicine

A trial counts when the registry's conditions or title name this, and some study a related question, such as insulin sensitivity in people with the condition. A registered trial shows a question being asked, not that the answer is yes.

Posted results

What trials on kidney disease reported

Latest phases and largest trials first. Each result is the first primary outcome as its sponsor posted it to the registry, which is not peer review.

TrialMedicinePhasePeopleResult
FLOWA Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney DiseaseSemaglutidePhase 33,533Number of Participants From Time of Randomization to First Occurrence of Onset of Persistent ≥50% Reduction in eGFR(CKD-EPI); Onset of Persistent eGFR(CKD-EPI) <15mL/Min/1.73m^2; Initiation of Chronic Renal Replacement Therapy; Renal Death; CV Death (Participants), From Week 0 up to Week 234. Semaglutide: 331; Placebo: 410.
AWARD-7A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)DulaglutidePhase 3577Change From Baseline in Hemoglobin A1c (HbA1c) (percentage of HbA1c), Baseline, 26 Weeks. Insulin Glargine: -1.13; Dulaglutide 0.75 mg: -1.12; Dulaglutide 1.5 mg: -1.19.
PIONEER 5Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal ImpairmentSemaglutidePhase 3324Change in HbA1c (Percentage of HbA1c), Week 0, week 26, In-trial. Oral Semaglutide 14 mg: -1.1; Placebo: -0.2.
NCT01620489Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal ImpairmentLiraglutidePhase 3279Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in HbA1c (%) (Glycosylated Haemoglobin) (percentage (%)), Week 0, Week 26. Lira 1.8 mg: -1.05; Placebo: -0.38.
REMODELA Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)SemaglutidePhase 3106Change in Kidney Oxygenation (Cortex), Blood Oxygenation-level Dependent Magnetic Resonance Imaging (BOLD MRI) (R2*) (Ratio of kidney oxygenation (cortex)), Baseline (week 0), End of treatment (week 52), Bilateral cortex. Semaglutide 1.0 mg: 0.98; Placebo: 1.00.
NCT02251431Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal SyndromeExenatidePhase 357Galectin-3 (pg/ml), 38 weeks, Baseline. Exenatide-extended Release: 9570.91; Placebo: 9266.7.
NCT01847313The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney DiseaseLiraglutidePhase 320MCP-1:Creatinine Ratio in Urine (ng/mmol), Up to 26 weeks. Liraglutide: 27.9; Control: 24.3.
RAISE-KTEffect of Subcutaneous Semaglutide on Kidney Transplant CandidacySemaglutidePhase 315Kidney Transplant Eligibility (Participants), Ascertained at the end of 9 months. Semaglutide: 3; Placebo: 2.
1981GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 DiabetesExenatidePhase 415Change From Baseline in Urinary Albuminuria Levels (microgram/mg creatinine), baseline and 52 weeks. Exenatide Extended Release: -32; Placebo: -12.
NCT04515849A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes MellitusSemaglutidePhase 2248The Primary Endpoint Was Percentage Change in UACR of Cotadutide at Different Dose Levels Compared to Placebo After 14 Weeks (Percentage change), Baseline to the end of 14 weeks of dosing. Cotadutide 100 ug: -10.96; Cotadutide 300 µg: -40.47; Cotadutide 600 µg: -44.60; Placebo ug: 4.60.
NCT05936151A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesRetatrutidePhase 2146Change From Baseline in Measured Glomerular Filtration Rate (mGFR) Using Iohexol Clearance at Week 24 (mL/min/1.73 m²), Baseline, Week 24. Placebo: -0.19; Retatrutide: -1.62.
NCT03961256Assess the Efficacy and Safety of Exenatide SR for the Prevention of Diabetes After Kidney TransplantationExenatidePhase 29Progression From Prediabetes to Diabetes (Participants), 12 months after transplantation. Exenatide SR Intervention Group: 0; Standard of Care: 1.
GLIMPEffects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney DiseaseDulaglutidePhase 27On ClinicalTrials.gov (clinicaltrials.gov)
NCT03482024A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney FunctionTirzepatidePhase 145Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide From Time Zero to Tlast (AUC[0-tlast]) (Nanogram*hour per Millilitre (ng*h/mL)), Predose, 8hours(h), 12h, 24h, 48h, 72h, 96h, 168h, 336h postdose. Tirzepatide - Control: 78400; Tirzepatide - Mild Renal Impairment: 81900; Tirzepatide - Moderate Renal Impairment: 98300; Tirzepatide - Severe Renal Impairment: 81200; Tirzepatide - End Stage Renal Disease (ESRD): 88500.
NCT05936138A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment.OrforglipronPhase 124Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-∞) of LY3502970 (nanogram*hour per milliliter (ng*hr/mL)), Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours postdose. LY3502970 (Normal Renal Function): 113; LY3502970 (Severe Renal Impairment): 167; LY3502970 (End-Stage Renal Disease): 108.
Recruiting now

Trials on kidney disease taking people now

The registry page names each site and who can enroll. Ask your clinician before joining one.

TrialMedicinePhaseExpected to finish
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) (clinicaltrials.gov/study/NCT07241390)OrforglipronPhase 3Aug 2031
The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect (clinicaltrials.gov/study/NCT06058585)SemaglutidePhase 3Dec 31, 2029
Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes (clinicaltrials.gov/study/NCT06082063)SemaglutidePhase 3Jul 1, 2029
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes (clinicaltrials.gov/study/NCT05390892)SemaglutidePhase 4Mar 1, 2029
QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy (clinicaltrials.gov/study/NCT07775846)MazdutidePhase 4Jun 30, 2029
A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China (clinicaltrials.gov/study/NCT07900438)SemaglutidePhase 4Jan 24, 2030
A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease (clinicaltrials.gov/study/NCT07239570)SemaglutidePhase 4Jun 2028
Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis (clinicaltrials.gov/study/NCT07017270)SemaglutidePhase 4Sep 2027
Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2 (clinicaltrials.gov/study/NCT06396416)SemaglutidePhase 4Dec 2026
Tirzepatide (Spartina) in Obese Kidney Transplant Recipients (clinicaltrials.gov/study/NCT07423247)TirzepatidePhase 4Sep 2026
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease (clinicaltrials.gov/study/NCT06717698)SemaglutidePhase 2Sep 17, 2026
Sit Less, Interact and Move More (SLIMM) 2 Study (clinicaltrials.gov/study/NCT05173714)SemaglutidePhase 2Mar 31, 2027
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes (clinicaltrials.gov/study/NCT05822609)SemaglutidePhase 2Dec 2027
The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients (clinicaltrials.gov/study/NCT05938712)SemaglutidePhase 2Mar 1, 2028
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD (clinicaltrials.gov/study/NCT07309094)SemaglutideNot phasedDec 31, 2028

The 15 largest of 18 recruiting.

From PubMed

Newest papers on GLP-1s and kidney disease

  • Kidney effects of tirzepatide across albuminuria, filtration markers, and clinical outcomes: a parent-trial-level systematic review and meta-analysis (pubmed.ncbi.nlm.nih.gov/43025465)

    Meta-analysis · Diabetes Res Clin Pract · Nov 13, 2026 · Li S et al.

  • Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial (pubmed.ncbi.nlm.nih.gov/42823485)

    Randomized trial · Nat Med · Oct 1, 2026 · Tuttle KR et al.

  • Comparative Cardiorenal Efficacy and Safety of Finerenone, SGLT2 Inhibitors, Semaglutide and Their Combination in Diabetic Kidney Disease (pubmed.ncbi.nlm.nih.gov/42750649)

    Meta-analysis · Diabetes Obes Metab · Sep 17, 2026 · Zhou Z et al.

  • Effects of Renin-Angiotensin Inhibitors, Sodium-Glucose Cotransporter 2 Inhibitors, Mineralocorticoid Receptor Antagonists and Glucagon-Like Peptide 1 Receptor Agonists on Kidney Outcomes in Patients With Type 1 Diabetes: A Systematic Review and Meta-Analysis (pubmed.ncbi.nlm.nih.gov/42733137)

    Meta-analysis · Diabetes Obes Metab · Sep 13, 2026 · Perry F et al.

  • Cardiovascular and renal outcomes of GLP-1 receptor agonists in type 2 diabetes mellitus: a systematic review and meta-analysis (pubmed.ncbi.nlm.nih.gov/42142362)

    Meta-analysis · Eur Heart J Qual Care Clin Outcomes · Sep 1, 2026 · Ahmed M et al. · cited by 2

  • Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis (pubmed.ncbi.nlm.nih.gov/42567173)

    Randomized trial · Lancet Diabetes Endocrinol · Aug 7, 2026 · Mann JFE et al. · cited by 2

Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.

Updated automatically

What changed in trials on kidney disease

  • TrialNew Aleniglipron study registered: Aleniglipron Renal Impairment Study (clinicaltrials.gov/study/NCT07946068)
  • TrialMazdutide study now recruiting (was not yet recruiting): QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy (clinicaltrials.gov/study/NCT07775846)
  • TrialSemaglutide study now recruiting (was not yet recruiting): Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide. (clinicaltrials.gov/study/NCT07391267)
  • TrialResults posted for a Retatrutide study: A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes (clinicaltrials.gov/study/NCT05936151)
  • TrialNew Liraglutide study registered: A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney Disease (clinicaltrials.gov/study/NCT07907965)
  • TrialNew Semaglutide study registered: A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China (clinicaltrials.gov/study/NCT07900438)
  • TrialNew Semaglutide study registered: Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant Access (clinicaltrials.gov/study/NCT07858331)
  • TrialSemaglutide study now active, not recruiting (was not yet recruiting): A Retrospective Real-World Cohort Study (clinicaltrials.gov/study/NCT07781371)

Written from each source's own record as it changes. Every change on GLPcompare

Questions

GLP-1s and kidney disease: common questions

What did the largest trial on kidney disease find?

FLOW (Semaglutide, 3,533 people): In people with type 2 diabetes and chronic kidney disease, major kidney events or death from kidney or heart causes were 24% less likely on semaglutide (331 against 410 first events; hazard ratio 0.76).

Is any GLP-1 FDA approved for kidney disease?

Yes: Ozempic. Ozempic's label: to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease.

Does insurance cover a GLP-1 for kidney disease?

Plans decide, and they usually tie coverage to a medicine's approved uses, so Ozempic is the place to start. Ask your plan whether it covers the medicine for this diagnosis and whether it needs prior authorization.

Which GLP-1 has been studied most for kidney disease?

Semaglutide, with 34 registered trials on it, then Exenatide and Liraglutide with 7 each. More trials do not mean better results: read what each posted.

Can I join a trial of a GLP-1 for kidney disease?

18 trials are recruiting on ClinicalTrials.gov now, listed on this page with their registry pages, which name each site and who can enroll.

Other conditions

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.